NeoTide
Alternative Names: Re-188 peptideLatest Information Update: 23 May 2006
At a glance
- Originator Bayer Schering Pharma
- Class Antineoplastics; Peptides; Radiosensitisers
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lung cancer
Most Recent Events
- 23 May 2006 Discontinued - Phase-I for Lung cancer in USA (unspecified route)
- 17 Aug 2000 Phase-I clinical trials for Lung cancer in USA (Unknown route)
- 21 Jun 2000 Preclinical development for Cancer in USA (Unknown route)